drugset / Trial / NCT00529984
A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
STUDY OBJECTIVES 1. The primary objective of this protocol is to determine the safety of immunization with CEA(6D) VRP in patients with advanced or metastatic CEA expressing malignancies. 2. The secondary objectives are to evaluate CEA-specific immune response to the immunizations and obtain preliminary data on response rate.
Timeline
- Start
- 2007-09
- Primary completion
- 2010-05
- Completion
- 2010-05